Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Feb 16;119(7):1665-70.
doi: 10.1182/blood-2011-10-388058. Epub 2011 Dec 19.

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H Moskowitz  1 , Matt J Matasar, Andrew D Zelenetz, Stephen D Nimer, John Gerecitano, Paul Hamlin, Steven Horwitz, Alison J Moskowitz, Ariela Noy, Lia Palomba, Miguel-Angel Perales, Carol Portlock, David Straus, Jocelyn C Maragulia, Heiko Schoder, Joachim Yahalom
Affiliations
Clinical Trial

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H Moskowitz et al. Blood. .

Abstract

We previously reported that remission duration < 1 year, extranodal disease, and B symptoms before salvage chemotherapy (SLT) can stratify relapsed or refractory Hodgkin lymphoma (HL) patients into favorable and unfavorable cohorts. In addition, pre-autologous stem cell transplant (ASCT) (18)FDG-PET response to SLT predicts outcome. This phase 2 study uses both pre-SLT prognostic factors and post-SLT FDG-PET response in a risk-adapted approach to improve PFS after high-dose radio-chemotherapy (HDT) and ASCT. The first SLT uses 2 cycles of ICE in a standard or augmented dose (ICE/aICE), followed by restaging FDG-PET scan. Patients with a negative scan received a transplant. If the FDG-PET scan remained positive, patients received 4 biweekly doses of gemcitabine, vinorelbine, and liposomal doxorubicin. Patients without evidence of disease progression proceeded to HDT/ASCT; those with progressive disease were study failures. At a median follow-up of 51 months, EFS analyzed by intent to treat as well as for transplanted patients is 70% and 79%, respectively. Patients transplanted with negative FDG-PET, pre-HDT/ASCT after 1 or 2 SLT programs, had an EFS of > 80%, versus 28.6% for patients with a positive scan (P < .001). This prospective study provides evidence that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT.

Trial registration: ClinicalTrials.gov NCT00255723.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment schema. aOne patient died of sudden death, and 1 patient did not complete ICE; b3 FDG-PET–negative patients did not receive GVD because they progressed on ICE; and c2 patients failed to mobilize cells, 3 patients progressed after ICE and GVD, 1 patient had an adverse reaction to liposomal doxil, and 1 patient was treated off study due to physician discretion.
Figure 2
Figure 2
Survival curves. (A) Intent-to-treat cohort. (B) Transplanted cohort.
Figure 3
Figure 3
EFS intent to treat by pre-ASCT response.
Figure 4
Figure 4
EFS for patients who received GVD.
Figure 5
Figure 5
EFS by PET and ENS results.
See this image and copyright information in PMC

References

    1. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. - PubMed
    1. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. - PubMed
    1. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208–4217. - PubMed
    1. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623. - PubMed
    1. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5240–5247. - PubMed

Publication types

MeSH terms

Substances

Associated data